✨ PMI: Making Advanced Treatment More Affordable for Our People✨

Pacific Medical Industries (PMI) is pleased to share that we have become the first factory in Myanmar to receive registration approval for Semaglutide, with our medicine, Seglupac.

💊 About Seglupac

Seglupac (Semaglutide) is an oral treatment for Type 2 Diabetes and Obesity, offering patients a more convenient choice beyond injections. It works by mimicking the GLP-1 hormone, helping to regulate blood sugar levels, reduce appetite, and lower the risk of serious complications, such as heart disease.

🧪 Innovation at PMI

PMI is proud to have its own Research & Development (R&D) department and employs skilled formulation scientists from around the world. This capability enables us to develop our own formulations for the latest molecules, ensuring that they can be produced locally and made more accessible to our people.

🌍 Why It Matters for Myanmar

Today: More than 4 million people in Myanmar are living with obesity and Type 2 Diabetes (8.4% of men, 12.6% of women). Until now, the original brands, Ozempic and Rybelsus, were available only at very high prices, making them difficult for most families to access. 

💡 Our Commitment

We are now able to produce the following strengths locally for patients who need them:

· Seglupac 3 (Semaglutide 3mg Tablet)

· Seglupac 7 (Semaglutide 7mg Tablet)

· Seglupac 14 (Semaglutide 14mg Tablet)

By ensuring reasonable pricing while maintaining international quality standards, we aim to alleviate the burden on patients and their families nationwide.

This approval is not just a company achievement—it is part of our ongoing journey to serve the health and well-being of the people of Myanmar. 🇲🇲❤️

#PMI #Seglupac #HealthcareForAll #DiabetesCare #ObesityTreatment